These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 27660217)
1. Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease. Hilario WF; Herlinger AL; Areal LB; de Moraes LS; Ferreira TA; Andrade TE; Martins-Silva C; Pires RG J Mol Neurosci; 2016 Dec; 60(4):453-464. PubMed ID: 27660217 [TBL] [Abstract][Full Text] [Related]
2. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease. Litim N; Bourque M; Al Sweidi S; Morissette M; Di Paolo T Neuropharmacology; 2015 Oct; 97():86-94. PubMed ID: 26006269 [TBL] [Abstract][Full Text] [Related]
3. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model. Rai SN; Yadav SK; Singh D; Singh SP J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287 [TBL] [Abstract][Full Text] [Related]
4. Lack of CCR5 modifies glial phenotypes and population of the nigral dopaminergic neurons, but not MPTP-induced dopaminergic neurodegeneration. Choi DY; Lee MK; Hong JT Neurobiol Dis; 2013 Jan; 49():159-68. PubMed ID: 22922220 [TBL] [Abstract][Full Text] [Related]
5. Medicinal plant Combretum leprosum mart ameliorates motor, biochemical and molecular alterations in a Parkinson's disease model induced by MPTP. Moraes LS; Rohor BZ; Areal LB; Pereira EV; Santos AM; Facundo VA; Santos AR; Pires RG; Martins-Silva C J Ethnopharmacol; 2016 Jun; 185():68-76. PubMed ID: 26994817 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of genistein on dopaminergic neurons in the mice model of Parkinson's disease. Liu LX; Chen WF; Xie JX; Wong MS Neurosci Res; 2008 Feb; 60(2):156-61. PubMed ID: 18054104 [TBL] [Abstract][Full Text] [Related]
7. Increased susceptibility of G-protein coupled receptor 6 deficient mice to MPTP neurotoxicity. Oeckl P; Ferger B Neuroscience; 2016 Nov; 337():218-223. PubMed ID: 27651149 [TBL] [Abstract][Full Text] [Related]
8. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress. Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333 [TBL] [Abstract][Full Text] [Related]
9. Endurance Exercise Mediates Neuroprotection Against MPTP-mediated Parkinson's Disease via Enhanced Neurogenesis, Antioxidant Capacity, and Autophagy. Jang Y; Kwon I; Song W; Cosio-Lima LM; Lee Y Neuroscience; 2018 May; 379():292-301. PubMed ID: 29559387 [TBL] [Abstract][Full Text] [Related]
11. Total glucosides of paeony (TGP) extracted from Radix Paeoniae Alba exerts neuroprotective effects in MPTP-induced experimental parkinsonism by regulating the cAMP/PKA/CREB signaling pathway. Zheng M; Liu C; Fan Y; Shi D; Jian W J Ethnopharmacol; 2019 Dec; 245():112182. PubMed ID: 31445131 [TBL] [Abstract][Full Text] [Related]
12. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice. Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056 [TBL] [Abstract][Full Text] [Related]
13. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration. Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292 [TBL] [Abstract][Full Text] [Related]
15. Systemically administered neuregulin-1β1 rescues nigral dopaminergic neurons via the ErbB4 receptor tyrosine kinase in MPTP mouse models of Parkinson's disease. Depboylu C; Rösler TW; de Andrade A; Oertel WH; Höglinger GU J Neurochem; 2015 May; 133(4):590-7. PubMed ID: 25581060 [TBL] [Abstract][Full Text] [Related]
16. Protective action of neuronal nitric oxide synthase inhibitor in the MPTP mouse model of Parkinson's disease. Watanabe Y; Kato H; Araki T Metab Brain Dis; 2008 Mar; 23(1):51-69. PubMed ID: 18030609 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of riluzole in MPTP-treated mice. Araki T; Kumagai T; Tanaka K; Matsubara M; Kato H; Itoyama Y; Imai Y Brain Res; 2001 Nov; 918(1-2):176-81. PubMed ID: 11684056 [TBL] [Abstract][Full Text] [Related]
18. Behavioral, Biochemical and Molecular Characterization of a Parkinson's Disease Mouse Model Using the Neurotoxin 2'-CH Herlinger AL; Almeida AR; Presti-Silva SM; Pereira EV; Andrich F; Pires RGW; Martins-Silva C Neuromolecular Med; 2018 Mar; 20(1):73-82. PubMed ID: 29332269 [TBL] [Abstract][Full Text] [Related]
19. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice. Jung HW; Son HY; Jin GZ; Park YK Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864 [TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]